431 related articles for article (PubMed ID: 24081945)
21. Methylation profiling in non-small cell lung cancer: clinical implications.
Morán A; Fernández-Marcelo T; Carro J; De Juan C; Pascua I; Head J; Gómez A; Hernando F; Torres AJ; Benito M; Iniesta P
Int J Oncol; 2012 Mar; 40(3):739-46. PubMed ID: 22076605
[TBL] [Abstract][Full Text] [Related]
22. A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis.
Hata A; Nakajima T; Matsusaka K; Fukuyo M; Morimoto J; Yamamoto T; Sakairi Y; Rahmutulla B; Ota S; Wada H; Suzuki H; Matsubara H; Yoshino I; Kaneda A
Int J Cancer; 2020 Jan; 146(2):388-399. PubMed ID: 31241180
[TBL] [Abstract][Full Text] [Related]
23. Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
Sato T; Soejima K; Arai E; Hamamoto J; Yasuda H; Arai D; Ishioka K; Ohgino K; Naoki K; Kohno T; Tsuta K; Watanabe S; Kanai Y; Betsuyaku T
Oncol Rep; 2015 Sep; 34(3):1137-45. PubMed ID: 26134684
[TBL] [Abstract][Full Text] [Related]
24. Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China.
Wang RQ; Long XR; Ge CL; Zhang MY; Huang L; Zhou NN; Hu Y; Li RL; Li Z; Chen DN; Zhang LJ; Wen ZS; Mai SJ; Wang HY
J Transl Med; 2020 Aug; 18(1):320. PubMed ID: 32819367
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients.
Ji X; Lin L; Shen S; Dong X; Chen C; Li Y; Zhu Y; Huang H; Chen J; Chen X; Wei L; He J; Duan W; Su L; Jiang Y; Fan J; Guan J; You D; Shafer A; Bjaanaes MM; Karlsson A; Planck M; Staaf J; Helland Å; Esteller M; Wei Y; Zhang R; Chen F; Christiani DC
Mol Oncol; 2020 Nov; 14(11):2759-2774. PubMed ID: 33448640
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide CpG island methylation analyses in non-small cell lung cancer patients.
Heller G; Babinsky VN; Ziegler B; Weinzierl M; Noll C; Altenberger C; Müllauer L; Dekan G; Grin Y; Lang G; End-Pfützenreuter A; Steiner I; Zehetmayer S; Döme B; Arns BM; Fong KM; Wright CM; Yang IA; Klepetko W; Posch M; Zielinski CC; Zöchbauer-Müller S
Carcinogenesis; 2013 Mar; 34(3):513-21. PubMed ID: 23172663
[TBL] [Abstract][Full Text] [Related]
27. Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.
Gentles AJ; Bratman SV; Lee LJ; Harris JP; Feng W; Nair RV; Shultz DB; Nair VS; Hoang CD; West RB; Plevritis SK; Alizadeh AA; Diehn M
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26286589
[TBL] [Abstract][Full Text] [Related]
28. A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer.
Shen S; Zhang R; Guo Y; Loehrer E; Wei Y; Zhu Y; Yuan Q; Moran S; Fleischer T; Bjaanaes MM; Karlsson A; Planck M; Staaf J; Helland Å; Esteller M; Su L; Chen F; Christiani DC
Mol Oncol; 2018 Jun; 12(6):913-924. PubMed ID: 29656435
[TBL] [Abstract][Full Text] [Related]
29. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Dong M; Yang Z; Li X; Zhang Z; Yin A
Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
[TBL] [Abstract][Full Text] [Related]
30. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
[TBL] [Abstract][Full Text] [Related]
32. An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers.
Robles AI; Arai E; Mathé EA; Okayama H; Schetter AJ; Brown D; Petersen D; Bowman ED; Noro R; Welsh JA; Edelman DC; Stevenson HS; Wang Y; Tsuchiya N; Kohno T; Skaug V; Mollerup S; Haugen A; Meltzer PS; Yokota J; Kanai Y; Harris CC
J Thorac Oncol; 2015 Jul; 10(7):1037-48. PubMed ID: 26134223
[TBL] [Abstract][Full Text] [Related]
33. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
34. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study.
Yang XY; Zhang J; Yu XL; Zheng GF; Zhao F; Jia XJ
J Cancer Res Ther; 2018; 14(Supplement):S65-S71. PubMed ID: 29578152
[TBL] [Abstract][Full Text] [Related]
35. Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects.
Zhang R; Chen C; Dong X; Shen S; Lai L; He J; You D; Lin L; Zhu Y; Huang H; Chen J; Wei L; Chen X; Li Y; Guo Y; Duan W; Liu L; Su L; Shafer A; Fleischer T; Moksnes Bjaanæs M; Karlsson A; Planck M; Wang R; Staaf J; Helland Å; Esteller M; Wei Y; Chen F; Christiani DC
Chest; 2020 Aug; 158(2):808-819. PubMed ID: 32113923
[TBL] [Abstract][Full Text] [Related]
36. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
Bossé Y; Dasgupta A; Abadier M; Guthrie V; Song F; Saavedra Armero V; Gaudreault N; Orain M; Lamaze FC; Melton C; Nance T; Hung T; Hodgson D; Abbosh C; Joubert P
Cancer Lett; 2024 Jul; 594():216984. PubMed ID: 38797230
[TBL] [Abstract][Full Text] [Related]
37.
Zhang W; Li T; Hu B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
[TBL] [Abstract][Full Text] [Related]
38. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
[TBL] [Abstract][Full Text] [Related]
39. A serum microRNA signature as a prognostic factor for patients with advanced NSCLC and its association with tissue microRNA expression profiles.
Guo J; Meng R; Yin Z; Li P; Zhou R; Zhang S; Dong X; Liu L; Wu G
Mol Med Rep; 2016 Jun; 13(6):4643-53. PubMed ID: 27081922
[TBL] [Abstract][Full Text] [Related]
40. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
Der SD; Sykes J; Pintilie M; Zhu CQ; Strumpf D; Liu N; Jurisica I; Shepherd FA; Tsao MS
J Thorac Oncol; 2014 Jan; 9(1):59-64. PubMed ID: 24305008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
